FY2026 EPS Forecast for Adherex Technologies Cut by Analyst

Key Points

• Wedbush has revised its FY2026 earnings per share (EPS) forecast for Adherex Technologies from $0.55 to $0.44, while the consensus estimate for the company's full-year earnings remains significantly lower at ($0.11) per share.
• Adherex Technologies' stock is currently rated as "Moderate Buy" with an average target price of $13.33, despite recent sell ratings from Weiss Ratings and Zacks Research.
• The company's shares are down 1.5%, trading at $8.44, with a market cap of $235.56 million and significant insider selling activity recorded.

Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Equities researchers at Wedbush decreased their FY2026 earnings per share (EPS) estimates for Adherex Technologies in a research note issued to investors on Monday, October 13th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $0.44 per share for the year, down from their previous forecast of $0.55. The consensus estimate for Adherex Technologies' current full-year earnings is ($0.11) per share.

Other equities analysts have also issued research reports about the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adherex Technologies in a report on Wednesday, October 8th. HC Wainwright reiterated a "buy" rating and issued a $13.00 target price on shares of Adherex Technologies in a research report on Thursday, August 21st. Craig Hallum increased their price target on shares of Adherex Technologies from $13.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday, August 15th. Wall Street Zen upgraded shares of Adherex Technologies from a "hold" rating to a "buy" rating in a research note on Friday, October 3rd. Finally, Zacks Research downgraded shares of Adherex Technologies from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $13.33.

Adherex Technologies Stock Down 1.5%

Shares of NASDAQ:FENC opened at $8.44 on Tuesday. The company has a 50-day moving average price of $8.81 and a 200 day moving average price of $7.81. Adherex Technologies has a 52 week low of $3.96 and a 52 week high of $9.92. The company has a market cap of $235.56 million, a P/E ratio of -20.09 and a beta of 0.64.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The business had revenue of $9.76 million during the quarter, compared to the consensus estimate of $9.52 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in FENC. AIGH Capital Management LLC acquired a new position in Adherex Technologies during the first quarter worth $2,199,000. Nuveen LLC acquired a new position in Adherex Technologies during the first quarter worth $158,000. AQR Capital Management LLC acquired a new position in Adherex Technologies during the first quarter worth $66,000. Finally, Jane Street Group LLC acquired a new position in Adherex Technologies during the first quarter worth $90,000. Institutional investors and hedge funds own 55.51% of the company's stock.

Insider Buying and Selling

In other Adherex Technologies news, Director Rosty Raykov sold 10,000 shares of Adherex Technologies stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $9.78, for a total value of $97,800.00. Following the transaction, the director owned 82,501 shares of the company's stock, valued at approximately $806,859.78. The trade was a 10.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Southpoint Capital Advisors Lp sold 26,900 shares of Adherex Technologies stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $9.59, for a total transaction of $257,971.00. Following the completion of the transaction, the insider directly owned 4,050,314 shares in the company, valued at approximately $38,842,511.26. The trade was a 0.66% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 87,114 shares of company stock worth $815,025. Insiders own 10.98% of the company's stock.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.